title: Antineoplastic effects of partially HLA-matched irradiated blood mononuclear cells in patients with renal cell carcinoma.
abstract: OBJECTIVE
  Vaccines, cytokines, and other biologic-based therapies are being developed as antineoplastic agents. Many of these agents are designed to induce an autologous immune response directed against the malignancy. In contrast, hematopoietic stem-cell transplantation is being developed as a form of allogeneic immunotherapy. This study tests the tolerance and antineoplastic activity of sequential infusions of partially HLA-matched allogeneic blood mononuclear cells (obtained from relatives) when administered outside of the context of a hematopoietic stem-cell transplantation. The cells are irradiated to prevent graft-versus-host disease.
  
  
  METHODS
  Fifteen patients with relapsed or refractory malignancies for which no standard therapy was available were enrolled onto a clinical trial designed to assess the tolerability and antineoplastic effects of irradiated partially HLA-matched blood mononuclear cells obtained from relatives.
  
  
  RESULTS
  There was disease regression in three patients with metastatic renal cell carcinoma during treatment. There was disease progression in six patients with metastatic renal cell carcinoma and two patients with metastatic melanoma during treatment. There was no change in disease state in several other patients.
  
  
  CONCLUSIONS
  Irradiated allogeneic blood mononuclear cells administered outside the context of hematopoietic stem-cell transplantation may induce disease responses in patients with relapsed or refractory malignancies. Transfusion of irradiated allogeneic blood mononuclear cells should be developed further as a novel therapeutic antineoplastic approach.
authors.affiliation: Division of Medical Oncology and Surgical Oncology, Robert Wood Johnson Medical School, New Brunswick, NJ 08903, USA. strairrk@umdnj.edu
authors.forename: Roger K
authors.initials: RK
authors.lastname: Strair
authors.forename: Dale
authors.initials: D
authors.lastname: Schaar
authors.forename: Daniel
authors.initials: D
authors.lastname: Medina
authors.forename: Mary B
authors.initials: MB
authors.lastname: Todd
authors.forename: Joseph
authors.initials: J
authors.lastname: Aisner
authors.forename: Robert S
authors.initials: RS
authors.lastname: DiPaola
authors.forename: Jacqueline
authors.initials: J
authors.lastname: Manago
authors.forename: Beth
authors.initials: B
authors.lastname: Knox
authors.forename: Amanda
authors.initials: A
authors.lastname: Jenkinson
authors.forename: Rachelle
authors.initials: R
authors.lastname: Senzon
authors.forename: Christina
authors.initials: C
authors.lastname: Baker
authors.forename: Dudek
authors.initials: D
authors.lastname: Liesel
authors.forename: Marie
authors.initials: M
authors.lastname: Ciardella
authors.forename: Mercy
authors.initials: M
authors.lastname: Kuriyan
authors.forename: Arnold
authors.initials: A
authors.lastname: Rubin
authors.forename: Edmund C
authors.initials: EC
authors.lastname: Lattime
mesh_terms: D000328:Adult; D000368:Aged; D002292:Carcinoma, Renal Cell / Q000628:therapy*; D017690:Cell Transplantation; D005260:Female; D006680:HLA Antigens; D006801:Humans; D007680:Kidney Neoplasms / Q000628:therapy*; D007694:Killer Cells, Natural / Q000276:immunology* / Q000528:radiation effects; D008297:Male; D008875:Middle Aged; D013601:T-Lymphocytes / Q000276:immunology* / Q000528:radiation effects
chemical_list: D006680:HLA Antigens